Improved AAV tropism is essential for gene therapy to reach its full potential. New capsid engineering techniques are taking on this challenge. Clinical translation of gene therapies has a history ...

With this ground-breaking invention, the Vericheck ddPCR Empty-Full Capsid Kit streamlines the AAV development to produce dependable results. Using ddPCR technology, obtaining absolute ...

In this talk, David Apiyo, Manager of Application Development at Sartorius (Göttingen, Germany), proposes a method that extends the use of AAVX biosensors to determine empty-to-full capsid ratios.

The capsid license follows an agreement between Dyno and Roche originally announced in May 2020 and marks Dyno’s first adeno-associated virus (AAV) capsid licensing and partnership completion.